909 (1.328 ÷ 6.372)], without a statistically significant association between KRAS mutation and other clinicopathological characteristics, such as high tumour grade [p = 0.030; OR: 0.280 (0.084 ÷ 0.933)] and pT4 invasion depth [p < 0.001); OR: 0.211 (0.088 ÷ 0.504)] (Table 2 and Table 3). The gene discussed is KRAS; the disease is neoplasm.